A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs Syndrome
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 24 Oct 2019 Planned End Date changed from 1 Jun 2020 to 1 Sep 2022.
- 24 Oct 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Sep 2022.
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.